Drug Profile


Alternative Names: GL-ONC1; GLV-1h68

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genelux Corporation
  • Developer Genelux Corporation; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Peritoneal cancer
  • Phase I Head and neck cancer; Malignant pleural effusion; Solid tumours

Most Recent Events

  • 07 Aug 2017 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater, Monotherapy) in USA (Intraperitoneal) (NCT02759588)
  • 01 May 2016 Phase-I clinical trials in Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT02759588)
  • 29 Apr 2016 Genelux Corporation plans a phase Ib trial for Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT02759588)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top